OTC standardized label flexibility supported by NDAC members at Sept. 29 meeting.
This article was originally published in The Tan Sheet
Executive Summary
OTC STANDARDIZED LABEL FLEXIBILITY SUPPORTED BY NDAC members at a Sept. 29 meeting in Rockville, Md. The Nonprescription Drugs Advisory Committee discussed labeling issues at a meeting immediately following an FDA public hearing on OTC drug labeling. After listening to more than five hours of presentations from industry, consumer groups, researchers and other interested parties, NDAC member Eric Brass, MD/PhD, Harbor-UCLA Medical Center, expressed a common opinion when he recommended that FDA "balance the issue of flexibility" as it considers standardizing OTC labels.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning